SEC Form 4 · accession 0001102624-16-002066
AEOLUS PHARMACEUTICALS, INC. · AOLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L McManus
Officer — President and CEO
Period of report
Mar 4, 2014
Accepted (ET)
Feb 3, 2016 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001261734
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $0.265 | Mar 4, 2014 | A | 250,000 | A | — | Mar 4, 2024 | Common Stock | 250,000 | 250,000 | D |
| Incentive Stock Option (right to buy)F1 | $0.2682 | Mar 4, 2015 | A | 250,000 | A | — | Mar 4, 2025 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Option will vest in equal monthly installments over a period of twelve months from the date of grant, provided that the reporting person remains an employee of the Company.